Methotrexate, a powerful medicine for cancer and inflammatory diseases, can cause serious brain and nerve damage that doctors don’t always recognize. According to Gram Research analysis, this neurotoxicity can cause sudden headaches, seizures, and stroke-like symptoms within days of treatment—sometimes after patients leave the hospital. While high-dose and spinal injections carry the highest risk, lower doses can also cause these problems, and current prevention and treatment options lack strong scientific evidence.
Methotrexate is a powerful medicine used to treat cancer and inflammatory diseases, but it can cause serious brain and nerve problems that doctors don’t always recognize. According to Gram Research analysis, these neurological side effects can happen suddenly with symptoms like headaches, seizures, or stroke-like symptoms, even in patients taking lower doses. This review examines what we know about how methotrexate damages the nervous system, what warning signs to watch for, and what treatments might help—while highlighting important gaps in our understanding that need more research.
Key Statistics
A 2026 review in the British Journal of Hospital Medicine found that methotrexate neurotoxicity can occur in patients receiving low-dose treatment, not just high-dose therapy, meaning the problem is likely more common than doctors currently recognize.
According to the 2026 state-of-the-art review, stroke-like symptoms from methotrexate often develop several days after administration when patients may be out of the hospital, requiring emergency care providers to recognize this condition.
The 2026 review identified that while preventative agents and treatments for methotrexate neurotoxicity have been identified, they currently lack robust scientific evidence, representing a critical gap in clinical care.
The Quick Take
- What they studied: How methotrexate, a common cancer and arthritis medicine, can damage the brain and nervous system, and what doctors should know about recognizing and treating these problems.
- Who participated: This is a review article that examined existing research and case reports about methotrexate neurotoxicity across different patient groups receiving the drug for cancer or inflammatory conditions.
- Key finding: Methotrexate can cause brain and nerve damage in patients receiving high doses or injections into the spine, but it may also happen in people taking lower doses—and symptoms can appear days after treatment when patients are home, making early recognition critical.
- What it means for you: If you or a loved one takes methotrexate and experiences sudden headaches, confusion, seizures, or stroke-like symptoms, seek emergency care immediately. Doctors need better training to spot these side effects early. Current prevention and treatment options exist but need stronger scientific evidence.
The Research Details
This is a review article, meaning the authors examined and summarized existing research, case reports, and clinical knowledge about methotrexate’s effects on the nervous system. Rather than conducting a new experiment, they gathered information from multiple sources to create a comprehensive overview of what’s currently known about this problem.
The review covers different types of methotrexate neurotoxicity—from immediate side effects like headaches and drowsiness to delayed problems like seizures and stroke-like symptoms that can develop days after treatment. It also examines long-term effects on thinking and behavior that some patients experience.
The authors focused on helping doctors recognize these neurological problems earlier and understand the current state of treatment and prevention strategies, while identifying areas where more research is desperately needed.
Review articles are important because they bring together scattered information from many studies and cases into one place, helping doctors understand the full picture of a problem. This is especially valuable for rare or under-recognized side effects like methotrexate neurotoxicity, which individual doctors might not see often enough to recognize. By summarizing what’s known and what’s unknown, this review helps improve patient safety and guides future research priorities.
This review was published in a respected medical journal (British Journal of Hospital Medicine) in 2026, suggesting it met peer-review standards. However, as a review article rather than original research, its strength depends on the quality of sources examined. The authors acknowledge significant gaps in evidence for treatments and prevention, which is honest and important. Readers should understand this represents a summary of existing knowledge rather than new experimental findings.
What the Results Show
Methotrexate can damage the nervous system in multiple ways and at different times. Some patients experience immediate effects like severe headaches and extreme drowsiness within hours of receiving the drug. Others develop more serious problems days later, including seizures or stroke-like symptoms (weakness, numbness, speech problems) that can be mistaken for actual strokes.
The review identifies that high-dose methotrexate and injections directly into the spine (intrathecal administration) carry the highest risk, but neurotoxicity can also occur in patients receiving standard lower doses—a finding that surprises many doctors. This means the problem is likely more common than previously recognized.
Long-term neurological effects are also documented, including persistent problems with memory, attention, and behavior that can significantly impact quality of life. These delayed effects may develop weeks or months after treatment and can be permanent.
Critically, the review emphasizes that stroke-like symptoms often appear after patients leave the hospital, meaning emergency room doctors and primary care physicians must be trained to recognize methotrexate neurotoxicity as a possible cause of sudden neurological symptoms.
The review identifies that the exact mechanism of how methotrexate damages nerve cells remains poorly understood, which hampers development of better prevention and treatment strategies. Several preventative approaches and treatments have been tried—including folinic acid supplementation, hydration protocols, and other supportive measures—but none have strong scientific evidence supporting their effectiveness. This represents a major gap in clinical care.
While methotrexate’s toxic effects on bone marrow, mouth tissues, liver, and kidneys have been well-documented for decades, neurological toxicity has received less attention and recognition. This review brings neurotoxicity into focus as an equally important concern that deserves more clinical awareness and research attention. The findings suggest that previous estimates of how common these neurological problems are may be too low, as many cases likely go unrecognized.
As a review article, this study doesn’t provide new experimental data. The strength of conclusions depends entirely on the quality and completeness of existing research examined. The authors acknowledge that treatment and prevention strategies lack robust evidence, meaning there’s currently no gold-standard approach proven to work. Additionally, because neurotoxicity is relatively uncommon and sometimes goes unrecognized, the true frequency of these problems may be underestimated in the literature reviewed. The review also highlights that much of the existing knowledge comes from case reports rather than large systematic studies, which limits confidence in some conclusions.
The Bottom Line
Patients taking methotrexate should be informed about potential neurological side effects and instructed to seek immediate emergency care if they experience sudden headaches, confusion, seizures, weakness, numbness, or speech problems. Healthcare providers should maintain high suspicion for methotrexate neurotoxicity when patients on this medication present with acute neurological symptoms. Current preventative measures (hydration, folinic acid supplementation) may be helpful but lack strong evidence—discuss with your doctor about what’s appropriate for your situation. More research is urgently needed to develop proven prevention and treatment strategies.
Anyone taking methotrexate for cancer or inflammatory conditions (like rheumatoid arthritis) should be aware of these risks. Family members and caregivers should also understand warning signs. Healthcare providers—especially emergency room doctors, neurologists, and primary care physicians—need better training to recognize methotrexate neurotoxicity. Patients receiving high-dose or intrathecal methotrexate face higher risk but should not assume lower doses are completely safe.
Acute neurological symptoms can appear within hours to days of methotrexate administration. Stroke-like symptoms may develop several days after treatment, sometimes after discharge from the hospital. Long-term cognitive and behavioral changes may develop over weeks to months. Recovery varies widely depending on severity and how quickly treatment is started.
Frequently Asked Questions
Can methotrexate cause brain damage even at low doses?
Yes. While high-dose methotrexate and spinal injections carry the highest risk, a 2026 review found that neurotoxicity can occur in patients receiving standard lower doses, making it more common than previously recognized.
What are the warning signs of methotrexate neurotoxicity I should watch for?
Watch for sudden severe headaches, extreme drowsiness, seizures, stroke-like symptoms (weakness, numbness, speech problems), confusion, or behavioral changes. These can appear within hours to days after methotrexate treatment, sometimes after leaving the hospital.
Is there a proven way to prevent methotrexate brain damage?
Current preventative approaches like folinic acid supplementation and hydration protocols may help, but a 2026 review found they lack strong scientific evidence. Discuss prevention strategies with your doctor based on your individual risk factors.
How long does it take to recover from methotrexate neurotoxicity?
Recovery varies widely depending on severity and how quickly treatment begins. Acute symptoms may resolve within days to weeks, but long-term cognitive and behavioral effects can persist for months or become permanent.
Should I stop taking methotrexate if I’m worried about brain damage?
Don’t stop without talking to your doctor. The benefits of methotrexate for cancer or inflammatory disease often outweigh the risks. Work with your healthcare team to monitor for symptoms and develop a safety plan.
Want to Apply This Research?
- If taking methotrexate, track the date and time of each dose and monitor for neurological symptoms daily for one week after treatment: headache severity (0-10 scale), alertness level, any seizure activity, weakness or numbness, speech difficulties, or confusion. Note any symptoms and their timing relative to methotrexate administration.
- Set phone reminders for the 3-7 days following methotrexate doses to check in on neurological symptoms. Create an emergency action plan: know the signs of methotrexate neurotoxicity and have emergency contact numbers readily available. Share symptom tracking data with your healthcare provider at each visit to help identify patterns.
- Maintain a long-term symptom log documenting any cognitive changes (memory, concentration), behavioral changes, or neurological symptoms between doses. Review this log with your doctor monthly. If you notice new or worsening neurological symptoms, report them immediately rather than waiting for your next scheduled appointment. Consider sharing your tracking data with both your oncologist/rheumatologist and primary care doctor.
This article reviews medical research about methotrexate neurotoxicity but is not a substitute for professional medical advice. If you take methotrexate and experience sudden neurological symptoms—including severe headaches, seizures, weakness, numbness, speech problems, or confusion—seek emergency medical care immediately. Do not stop taking methotrexate without consulting your doctor. All treatment decisions should be made in consultation with your healthcare provider, who understands your individual medical situation, risk factors, and treatment goals. This information is current as of June 2026 and may not reflect future research developments.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.